Stockreport

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay [Yahoo! Finance]

INmune Bio Inc. - Common stock  (INMB) 
PDF on developing treatments that harness the patient's innate immune system to fight disease, is delighted to announce the successful completion of the extended stability v [Read more]